1.17
price down icon3.31%   -0.04
pre-market  Vorhandelsmarkt:  1.25   0.08   +6.84%
loading
Schlusskurs vom Vortag:
$1.21
Offen:
$1.22
24-Stunden-Volumen:
206.28K
Relative Volume:
0.15
Marktkapitalisierung:
$19.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.78M
KGV:
-1.3273
EPS:
-0.8815
Netto-Cashflow:
$-4.71M
1W Leistung:
+0.00%
1M Leistung:
+10.38%
6M Leistung:
+69.86%
1J Leistung:
+40.90%
1-Tages-Spanne:
Value
$1.15
$1.23
1-Wochen-Bereich:
Value
$1.14
$1.2546
52-Wochen-Spanne:
Value
$0.51
$5.01

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Name
Firmenname
Mira Pharmaceuticals Inc
Name
Telefon
813-369-5150
Name
Adresse
1200 BRICKELL AVENUE, MIAMI
Name
Mitarbeiter
6
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
MIRA's Discussions on Twitter

Vergleichen Sie MIRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
MIRA
Mira Pharmaceuticals Inc
1.17 19.38M 0 -12.78M -4.71M -0.8815
Drug Manufacturers - General icon
LLY
Lilly Eli Co
742.35 705.53B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
81.03 359.79B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
148.15 344.63B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
172.61 305.03B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
96.24 251.88B 63.17B 12.15B 14.84B 4.77

Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten

pulisher
Jan 15, 2025

International Assets Investment Management LLC Invests $29,000 in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World

Jan 15, 2025
pulisher
Jan 15, 2025

MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 1.7% – Should You Sell? - Defense World

Jan 15, 2025
pulisher
Jan 07, 2025

AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com

Jan 07, 2025
pulisher
Jan 05, 2025

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation - Yahoo Finance

Jan 05, 2025
pulisher
Dec 23, 2024

Zacks Small Cap Has Pessimistic Outlook of MIRA Q4 Earnings - Defense World

Dec 23, 2024
pulisher
Dec 22, 2024

Mira Pharmaceuticals appoints new accounting firm By Investing.com - Investing.com South Africa

Dec 22, 2024
pulisher
Dec 21, 2024

Mira Pharmaceuticals appoints new accounting firm - Investing.com

Dec 21, 2024
pulisher
Dec 21, 2024

Why Wall Street Expects This Growth Stock To Soar 99% In 2025 - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

StatementProposed Amendments To The Air Passenger Protection Regulations - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

Should You Buy Joby Aviation Stock While It's Below $10? - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

C3.ai Stock: Buy, Sell, Or Steer Clear? - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

Is Xcel Energy Stock Underperforming The Nasdaq? - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

2 Fantastic Beaten-Down Growth Stocks Down 35% And 21% To Buy - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

Missed Out on Nvidia: 1 No-Brainer Artificial Intelligence (AI) Stock to Buy Before It Crushes the Market in 2025, and Beyond - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

MIRA Pharmaceuticals Submits IND for Ketamir-2, Targeting Unmet Needs in Neuropathic Pain Treatment - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

MIRA Pharmaceuticals Submits IND for Ketamir-2On December 19, 2024, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) disclosed that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2, - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

Stocks In Play: Canacol Energy Ltd. - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Grain Spreads: Profit Taking Theme - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Stocks Rally On Dovish PCE Inflation Report - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

The Current State Of HR Is Unacceptable - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Gilead Stock Gains 15.4% In A Year: Should You Buy, Sell Or Hold? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Is Alexandria Real Estate Stock Underperforming The Nasdaq? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Is W.R. Berkley Stock Outperforming The Dow? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

PayPal Rises 40% In A Year: To Buy Or Not To Buy The PYPL Stock? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

US proposes voluntary guidelines for self-driving vehicles in waning days of Biden administration - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Takeaways From The Associated Press’ Reporting On Prison Labor In Alabama - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Arabica Coffee Recovers On Weaker Dollar And Smaller Brazilian Crop - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Medtronic Stock Declines 5.6% In A Month: Time To Buy The Dip? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Is PPG Industries Stock Underperforming The S&P 500? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Stocks Regain Footing On Dovish PCE Inflation Report - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Enterprise Products Stock Rises 25% YTD: Should You Buy Now Or Avoid It? - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Three Reasons Why PESI Is Risky And One Stock To Buy Instead - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

SCARBOROUGH INNOVATES PARTNERS WITH SUNRAY VENTURE CAPITAL TO ACCELERATE LOCAL STARTUPS WITH 'CATALYST IGNITE' - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Knightscope K7 Alpha Testing Underway And 2024 Recap - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Take-Two (NASDAQ:TTWO): Strongest Q3 Results From The Video Gaming Group - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Stocks Pare Losses on Dovish PCE Report, But Threats Remain from Triple-Witching and Government Shutdown - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

3 Reasons To Sell BALY And 1 Stock To Buy Instead - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Rude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Crude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

2025 Picks: 2 Stocks To Buy Now For 50% Upside - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Three Reasons Why GPRO Is Risky And One Stock To Buy Instead - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Beyond Reality: Investing In AR/VR Tech For Future Gains - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Federal Reserve's Preferred Inflation Gauge Shows Price Pressures Eased Last Month - Barchart

Dec 20, 2024
pulisher
Dec 19, 2024

The number of Americans applying for unemployment benefits falls significantly after last week's big jump - Barchart

Dec 19, 2024
pulisher
Dec 19, 2024

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire

Dec 19, 2024
pulisher
Dec 19, 2024

MIRA Pharmaceuticals Submits FDA Application for Breakthrough Pain Treatment Targeting $3.1B Market - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

3 Best Industrials Sector Picks For Long-Term Investors In 2025 - Barchart

Dec 19, 2024
pulisher
Dec 19, 2024

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment - Benzinga

Dec 19, 2024
pulisher
Dec 18, 2024

US stocks fall sharply and Dow tumbles 1,100 points after the Fed hints at just 2 rate cuts for 2025 - Barchart

Dec 18, 2024
pulisher
Dec 18, 2024

OUTFRONT Media Stock Rises 33% In 6 Months: Will The Trend Last? - Barchart

Dec 18, 2024

Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$92.96
price up icon 1.22%
drug_manufacturers_general SNY
$51.69
price up icon 1.87%
$274.81
price up icon 0.99%
drug_manufacturers_general PFE
$26.64
price up icon 1.29%
drug_manufacturers_general NVS
$99.73
price up icon 2.26%
drug_manufacturers_general MRK
$96.24
price down icon 1.72%
Kapitalisierung:     |  Volumen (24h):